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TGF-β1 is an immunoregulatory cytokine that regulates immune cell proliferation, survival, differentiation, and
migration. Compelling evidence has demonstrated a strong association between the immune and skeletal systems
(so called Osteoimmunology), such as the critical role of TGF-β1 in the development and maintenance of the
skeletal tissue. This review provides an overview of the mechanisms in which TGF-β1 interacts with bone
component cells, such as osteoblasts, osteoclasts, chondrocytes, mesenchymal stem cells, and hematopoietic stem
cells, in concert with other cytokines and hormones.Introduction
Bone is a rigid organ that constitutes part of the endoskel-
eton of vertebrates. It serves multiple functions; providing
mechanical support for joints and tendons, protecting soft
tissue or various organs from mechanical stress or trauma,
storing minerals, generating hematopoietic cells, and pro-
ducing hormones. These many functions are regulated by
several soluble factors. Interestingly, accumulated evidence
indicates that transforming growth factor beta 1 (TGF-β1)
plays a critical role in bone formation, mineral storage, and
hematopoietic cell generation. In addition, recent progress
in the study of the cross-talk between the skeletal system
and the immune system (termed osteoimmunology) has
revealed shared components and mechanisms between the
two systems [1]. This review highlights recent findings fo-
cusing on the role of TGF-β1 in bone metabolism and
osteoimmunology.Function of TGF-β1 in the immune system
TGF-β1 is a one of the most potent regulatory cytokines
with diverse effects on hematopoietic cells. In the immune
system, TGF-β1 induces and maintains immune tolerance
by regulation of lymphocyte proliferation, differentiation,
and survival. Disruption of TGF-β1 results in a dysregu-
lated immune system [2], leading to inappropriate immune
cell activation, inflammation, cancer (Leukemia and malig-
nant lymphoma etc) and autoimmune diseases [3]. In fact,
TGF-β1-deficient mice (TGF-β1ko) die within 2-3 weeks* Correspondence: wchen@dir.nidcr.nih.gov
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distribution, and reproduction in any mediumafter birth due to lymphocyte and monocyte infiltration of
multiple vital organs [3,4]. CD4+Foxp3+ T cells that pre-
dominantly produce anti-inflammatory cytokines (TGF-β,
IL-10), but not inflammatory cytokines (IFN-γ, TNF-α, and
IL-17) are known as regulatory T cells (Tregs). They inhibit
the action of other effector T cells through soluble factors
(TGF-β or IL-10) or cell-to-cell contact [5]. It is well
known that TGF-β suppresses inflammatory cytokine pro-
duction by effector T cells, and additionally, it drives the
differentiation of naïve T cells to CD4+CD25+Foxp3+ Tregs
[6]. Moreover, TGF-β controls the initiation and resolution
of inflammatory responses through the regulation of
chemotaxis, activation, and survival of lymphocytes [2],
natural killer cells [7], dendritic cells [8], macrophages [9],
mast cells [10], and granulocytes [11]. These findings indi-
cate that TGF-β plays critical roles in the regulation of im-
mune responses.
Bone component cells in bone remodeling
Bone remodeling is a lifelong process where mature
bone tissue is removed from the skeleton (a process
called bone resorption) and new bone tissue is generated
(a process called bone formation). An imbalance be-
tween bone resorption and bone formation results in
many metabolic bone diseases, such as osteoporosis and
Camurati-Engelmann disease [12,13]. The cells responsible
for bone formation are known as osteoblasts which secrete
new bone, and those responsible for bone resorption are
known as osteoclasts, which break bone down. Osteoblasts
arise from mesenchymal stem cells (MSCs) located in bone
marrow, and Osteoclasts are generated from hematopoietictral Ltd. This is an Open Access article distributed under the terms of the
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osteoclast differentiation, and therefore balances bone for-
mation and resorption [14] (Figure 1).
The TGF-β family contains three closely related mam-
malian isoforms—TGF-β1, -β2, and -β3, yet TGF-β1
constitutes the largest sources of TGF-β in bone [15]. In
mice, TGF-β1 protein is detected in bone marrow cells,
chondrocytes, and the cartilaginous matrix [16]. As dis-
cussed in the next chapter, TGF-β1 regulates bone for-
mation through enhancement of osteoblast proliferation
[17], differentiation[18], and chemotactic attraction[19],
and also extracellular matrix and proteoglycan synthesis
of chondrocyte precursor cells [20]. We will discuss how
TGF-β1 maintains bone homeostasis through regulating
bone-forming cells, individually.
TGF-β1 and osteoblasts
Osteoblasts are mononucleated cells that are responsible
for bone formation. They arise from osteoblastic precur-
sors located in the deeper layer of periosteum and the
bone marrow, and produce a matrix of osteoid, which is
composed mainly of type I collagen [21]. TGF-β1 has a
variety of widely recognized roles in bone formation. For
example, TGF-β1 enhances osteoblast proliferation [17],
blocks apoptosis of osteoblasts [18], and also recruits
osteoblastic precursors or matrix-producing osteoblasts
to the site through chemotactic attraction [19]. In
addition, TGF-β1 enhances the production of extracellu-
lar bone matrix protein by osteoblasts in the early stages
of osteoblast differentiation [22]. On the other hand,Figure 1 Five major role of TGF-β1 in osteoimmunity are shown. (1) T
differentiation into chondrocytes. (2) TGF-β1 promotes osteoblast progenit
enhances osteoblast proliferation, and downregulates the expression of RA
osteoclast maturation. (5) TGF-β keeps hematopoietic stem cells (HSC) in hTGF-β1 inhibits the later phase of osteoblast prolifera-
tion and mineralization [23]. It has been previously
reported that both TGF-β receptor I and receptor II ex-
pression in murine, rat, and human osteoblasts was
decreased during osteoblast differentiation, which may
imply that osteoblasts are less sensitive to TGF-β1 in the
late phase of their differentiation [24]. The later stages
are positively regulated by bone matrix proteins (BMP),
which are members of the TGF-β superfamily [25].
Therefore, TGF-β1 cooperates with BMP to regulate the
differentiation of osteoblasts.
Runt-related transcription factor 2 (Runx2), also
known as core-binding factor subunitalpha-1 (Cbfa1), is
a DNA-binding transcription factor important in speci-
fying osteogenic lineage [26]. Runx2 is the master tran-
scription factor in bone formation, and several reports
indicated that it is regulated by TGF-β1 and BMP-2. In
the initial phase of osteoblastic differentiation (differenti-
ation of MSCs to osteoblast progenitor cells), Runx2
inhibited differentiation of MSCs to types of cells other
than osteoblasts, which required coordinated action be-
tween Runx2 and BMP2-induced Smad5 [27]. In the sec-
ond phase of their differentiation (from osteoblast
progenitor cells to osteoblasts), TGF-β1 induced the ex-
pression of Runx2, which cross-talks with beta-catenin
signaling to promote differentiation [28]. However, in
the final differentiation stages of osteoblasts (mature
osterblasts), TGF-β1 opposes BMP-2 actions [27].
Smad3, activated by TGF-β1, physically interacts with
Runx2 at Runx2-responsive elements, and suppressesGF-β1 stimulates the proliferation of MSCs, and promotes their
or’s differentiation into osteoblast. (3) High concentration of TGF-β1
NKL of osteoblast. (4) Low concentration of TGF-β1 promoted
ibernation state.
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ation of mature osteoblasts into osteocytes, and maintains
them in a resting state. Thus, TGF-β1 may promote osteo-
cyte development by downregulating Runx2 in mature
osteoblasts [18]. These findings indicate that TGF-β1 finely
tunes osteoblast differentiation.
TGF-β1 and osteoclasts
The role of TGF-β1 in osteoclastogenesis and bone re-
sorption is very complex and controversial. It is clear
that TGF-β1 mediates osteoclasts functions, such as
their maturation [29], apoptosis [30], and the recruit-
ment of osteoclast precursors from spleen or bone mar-
row [31]. Several reports indicated that TGF-β1 had a
biphasic effect on the osteoclast maturation. TGF-β1
induces osteoclastogenesis of hematopoietic precursor
and other osteoclastic precursors when it is added into
the culture with receptor activator of nuclear factor
kappa B ligand (RANKL) and macrophage colony stimu-
lating factor (M-CSF) [32]. TGF-β1 triggers the expres-
sion of nuclear kappa B (NF-κB) and receptor activator
of nuclear factor kappa B (RANK) in osteoclast precur-
sors, and RANKL-RANK interaction is important for
prolonged survival and augmented differentiation of
osteoclast precursors into osteoclasts [32]. On the other
hand, when osteoclast precursors were cultured with
osteoblasts, it seemed that osteoclast activation was atte-
nuated especially when they were stimulated with high
concentrations of TGF-β1 (1-10 ng/ml), while low con-
centrations of TGF-β1(1-10 pg/ml) promoted osteoclast
maturation [33]. High concentrations of TGF-β1 up-
regulated the expression and secretion of osteoproteo-
gerin (OPG) and down regulated that of RANKL by
osteoblasts [34]. OPG is a decoy receptor for RANKL,
and inhibits the RANKL-RANK interaction by binding
to RANKL on osteoblasts [35]. As a result, the differenti-
ation of osteoclast precursors into mature osteoclasts
mediated by RANKL-RANK is inhibited by OPG released
from osteoblasts.
RANKL-RANK-OPG axis and osteoimmunology
The RANKL-RANK-OPG axis is an important signaling
system functioning both in bone and immune cell com-
munication. RANKL expressed on T cells or soluble
forms of RANKL are able to induce matured osteoclasts.
RANK is also expressed on dendritic cells, and RANKL
activates dendritic cells by binding to RANK. RANKL/
RANK signaling inhibited apoptosis of dendritic cells,
resulting in an increase in dendritic cell-mediated T cell
proliferation in a mixed leukocyte reaction [36]. OPG is
expressed on monocytes, T cells and B cells [37]. Inter-
estingly, cytokines stimulating the osteoclastogenesis,
such as IL-1β, IL-6, IL-17, and TNF-α increased the ex-
pression of RANKL with decrease of OPG expression inosteoblasts [37]. These findings suggest that RANKL-
RANK-OPG axis may regulates immune responses. More
recently, RANKL-RANK-OPG axis has been reported to
be involved in the pathogenesis of degenerative bone dis-
eases, such as rheumatoid arthritis and psoriatic arthritis,
post menopausal osteoporosis, and bone metastasis
[37,38]. Novel strategic treatments are emerging that are
based on an understanding of the functional status of the
OPG/RANK/RANKL triad.
TGF-β1 and mesenchymal stem cells
MSCs are muitipotent progenitor cells that have the abil-
ity to differentiate into mesenchymal lineages, including
osteoblasts (bone), chondrocytes (cartilage) and adipo-
cytes [39]. The differentiation, and function of MSCs can
be regulated by TGF-β1. For example, TGF-β1 stimulates
the proliferation of MSCs and promotes their differenti-
ation into chondrocytes [40]. TGF-β1 promotes chon-
drogenesis as well as the early phase of osteogenesis,
however in the absence of BMPs, TGF-β1 is unable to
promote differentiation of MSCs into osteoblasts as
described previously [27].
MSCs have potent immunosuppressive effects through
cell-to-cell contact and by secreting soluble factors. They
have a clear potential for clinical application for the re-
pair of damaged tissue [41] and in the therapy of auto-
immune diseases and chronic inflammation [42]. Soluble
factors secreted by MSCs include indoleamine 2,3-dioxy-
genase (IDO), prostaglandin E2 (PGE2), and TGF-β
which all plays a major role in MSC-mediated suppres-
sion of T cell proliferation induced by mitogens or
alloantigens [43,44]. IDO metabolizes tryptophan to
kynurenine, which causes depletion of local tryptophan
and reduction of lymphocyte proliferation [45,46]. PGE2
is a powerful mediator that inhibits T cell mitogenesis
and IL-2 production [47]. Park et al. recently reported
that TGF-β1-transduced MSCs, but not control MSCs,
suppressed the development of type II collagen-induced
arthritis (CIA). In vivo treatment with TGF-β-transduced
MSCs reduced bone erosion and cartilage destruction by
suppressing type II collagen-specific T cell proliferation,
by down-regulating proinflammatory cytokine produc-
tion (IL-6, TNF-α, and IL-17), and by increasing the
number of type II collagen-specific CD4+Foxp3+ Tregs
in the spleen [48]. These findings suggested that TGF-β
produced by MSCs in vivo could play a key role in per-
ipheral tolerance and bone repair.
TGF-β And hematopoietic stem cells in bone marrow
Hematopoiesis is the formation of blood cellular compo-
nents (red blood cells, white blood cells, and platelets),
and critical to maintain their number in the peripheral
circulation. Hematopoietic stem cells (HSCs) reside and
self-renew in the bone marrow (BM) niche, and have the
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blood cell types. The term ‘BM niche’ was introduced
in the 1980s to define the spatial and temporal struc-
ture harboring stem cells [49]. Many different cell types
have been characterized as contributing to the forma-
tion of HSC BM niches, such as osteoblasts, endothelial
cells, MSCs, and reticular cells [50]. In the BM niche,
most of the HSCs are kept in hibernation or undiffer-
entiated states and few cells are recruited into the cell
cycle at long intervals, on average every 1 to 2 months
[51]. Tight regulation of HSCs’ proliferation and differ-
entiation is vital to retain the high quality of HSCs.
This process is also critical to avoid autoimmune dis-
eases or hematologic malignancy triggered by abnormal
HSCs released from BM to periphery. HSCs outside the
niche do not self-renew and commence the process of
differentiation to produce mature blood cells [51], indi-
cating that the presence of BM niche is critical for
HSCs homeostasis.
Recently, TGF-β has been reported to contribute to
the formation of HSC niches. Yamazaki et al. reported
that TGF-β produced by glial cells (one of the compo-
nents of BM niche) was critical for the maintenance of
BM niche [52]. They demonstrated that TGF-β type II
receptor-deficient HSCs showed impaired long-term
self-renewal activity. They also demonstrated that latent
TGF-β, produced by a variety of BM cells, was broadly
distributed within BM, while, active TGF-β was exclu-
sively detectable in glial cells that lay in parallel with
blood vessels. Since two distinct areas (perivascular area
and endosteal area) have been characterized as HSCs
niches [50], their finding suggested that active TGF-β
released by glial cells has a critical role in the perivascu-
lar BM niche. MSCs and osteoblasts, which are the com-
ponents of the endosteal niche, recruit HSCs and
maintain their survival by producing HSCs promoting
factors [50]. However, it remains unknown if TGF-β pro-
duced by MSCs is critical for the maintenance of BM
niche. Further investigation is required to establish this
new concept.
TGF-β and T cells in osteogenesis
The role of TGF-β signaling in T cells and the effect of
this upon osteogenesis was previously investigated by
Gao et al [53]. They reported that disruption of T cell
specific TGF-β signaling led to bone loss. T cells puri-
fied from CD4 dominant negative TGF-β RII mice pro-
duced more TNF-α and RANKL than wild type mice.
These factors, in concert, stimulated osteoclasts forma-
tion and activity, which resulted in impaired skeletal
maturation and bone loss in estrogen repleted mice
(osteoporosis model mice). In vivo treatment with a
TGF-β1 expression vector restored bone loss through
deactivating effector T cell function, suggesting thatTGF-β1 signaling in T cells could modify bone metab-
olism. In addition to the effects of TGF-β1, TGF-β2
also influences T cells effctor function which has impli-
cations for osteogenesis. TGF-β2 inhibits T cell activa-
tion through TGF-βR2, suggesting that the absence of
TGF-β2-mediated signaling may be a candidate of dys-
regulated production of TNF-α and RANKL in CD4
dominant negative TGF-β RII mice. Notably, it has
been reported that TGF-β2 stimulates synthesis of
TGF-β1 in chondrocytes and osteoblasts within newly
generated bone and cartilage, indicating a positive auto-
regulation of TGF-β [54]. Together, these results suggest
that TGF-β2 signaling play a regulatory role in T cell ac-
tivation and bone metabolism.
TNF-α has been previously reported to promote osteo-
blast apoptosis [55] and osteoclasts genesis from bone
marrow macrophages [56]. TGF-β1 attenuates TNF-α-
induced osteoblasts apoptosis and bone resorption [57].
Since TNF-α plays a pathological role in the develop-
ment of rheumatoid arthritis (RA), patients with severe
RA are treated with anti-TNF-α therapy [58]. Interest-
ingly, it has been reported that anti-TNF-α therapy
enhanced FoxP3+ regulatory T cells in patients with RA
via induction of TGF-β [59]. Thus, these data suggest
that TGF-β protects bone from TNF-α induced bone
damage by suppressing effecter T cell function and/or
promoting induction of regulatory T cells. Besides TNF-
α IL-6, IL-17, and IL-23 can induce osteoclast differenti-
ation resulting in bone resorption [60]. For instance, it
has been reported that IL-17 promotes osteoclastgen-
esis via RANKL induction on osteoblasts [61]. Low
levels of TGF-β synergize with IL-6 to induce Th17
differentiation, whereas high levels of TGF-β result in
development of Foxp3+ regulatory T cells [62]. Fur-
thermore, IL-17 and TNF-α have been shown to induce
IL-6 and IL-23 expression in synovial fibroblast [63].
These findings could suggest that TGF-β regulates osteo-
clast genesis by controlling Th17 differentiation.
RA is a disease mediated by both Th1 and Th17 cells,
as both cell types accumulate in the joints of CIA mice
[64]. In general, TGF-β inhibits Th1 cells differentiation,
however, recent findings indicated that RA is not a Th1-
mediated disease. For example, IFN-γ (Th1 related cyto-
kine) was hardly detected in the synovial fluids of RA
patients [65]. Moreover, IFN-γ has been shown to inhibit
osteoclasts genesis in human [66]. Thus, the role of Th1
and Th17 cells in RA is still an open question.
TGF-β1 and regulatory T cells in osteogenesis
Tregs induce and maintain immune tolerance, however
several groups recently reported that regulatory T cells
also promote bone formation. We have recently shown
that CD4+ Foxp3+ Tregs improved MSCs-mediated bone
formation [67] by suppressing the number of infiltrating
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and TNF-α in the MSCs implants. However, IL-4 and
IL-10 levels were not affected. These findings suggest
that Tregs-mediated anti-inflammatory milieu could
promote favorable conditions for bone regeneration.
Zaiss et al. reported that Foxp3-Tg mice that overexpress
Foxp3 had higher bone mass and were protected from
ovariectomy-induced bone loss [68]. The increase in
bone mass resulted from impaired osteoclasts differen-
tiation and bone resorption in vivo, not from up-
regulation of bone formation. Surprisingly, adoptive
transfer of regulatory T cells into RAG-1-/- mice (mice
who have no mature T and B cells in lymphoid
organs) increased the bone mass, indicating that regu-
latory T cells could directly affect bone homeostasis
without other T cell lineages engagement. Collectively,
these findings provide evidence that regulatory T cells
promoted bone formation.
TGF-β1 and Hormones
TGF-β1 interacts with soluble factors like hormones, such
as estrogen, gluco-corticoids, parathyroid hormone (PTH),
and vitamin D. Estrogen stimulates TGF-β1 production in
osteoblasts, and promotes osteoblasts proliferation and dif-
ferentiation. Moreover, estrogen prevents bone loss by pro-
moting osteoclasts apoptosis through a TGF-β dependent
mechanism [69]. Estrogen receptor α (ER- α) was identified
as a co-repressor for Smad activity, and Smad3 was identi-
fied as an enhancer of ER-α mediated transcriptional activ-
ity, indicating that Estrogen and TGF-β1 coordinate
actions during bone formation [70].
Gluco-corticoids are known to promote apoptosis of
osteoblasts and also inhibit their proliferation and differen-
tiation while promoting the differentiation of osteoclasts
[71]. Gluco-corticoids upregulate TGF-β1 expression in
osteoblasts, however, unlike estrogen, Gluco-corticoids
synergise with TGF-β enhanced osteoclast formation by
stimulating the priming of osteoclast progenitors for dif-
ferentiation into osteoclasts [72]. PTH, a polypeptide
secreted by parathyroid glands, enhances bone formation
by increasing TGF-β mediated type I collagen production
in osteoblasts. However, PTH concomitantly promotes
bone resorption by binding to PTH receptor on osteo-
blasts and stimulating osteoblasts to increase their ex-
pression of RANKL but inhibits their expression of OPG
[73]. Thus, PTH functions as a double-edged sword for
bone metabolism.
Vitamin D is an important regulator of calcium
homeostasis in bone. It stimulates bone formation by
promoting osteoblast differentiation and extracellular
matrix mineralization. Moreover, it inhibits PTH-
mediated bone resorption [74]. Vitamin D receptor
(VDR) is expressed on osteoblast precursors, and vitamin
D signals via VDR result in up-regulation of a boneformation gene, osteocalcin [75]. Osteocalcin released by
osteoblast precursors induces maturation of osteoblasts
[76]. The effect of TGF-β1 on vitamin D functioning
seems to diverge at the Smad3/MAPK level. Smad3 has
been shown to act as a coactivator of vitamin D signaling
to activate osteocalcin expression in a study using fibro-
blasts [77]. Interestingly, Smad3 binding elements and
vitamin D responsive elements are closely located in the
osteocalcin promoter [77]. On the other hand, TGF-β1
mediated AP-1/MAPK signaling pathways seem to
antagonize osteocalcin synthesis in an osteosarcoma cell
line [78]. In conflicting reports using mouse osteoblasts,
TGF-β1 and vitamin D have been shown to both syner-
gize and antagonize each other in bone formation
[79,80]. Thus, it appears that signals transmitted through
Smad3 and MAPK pathways evoke opposite effects on
vitamin D functioning.
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